• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

    11/4/24 3:11:06 PM ET
    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMZN alert in real time by email

    BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024, sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed attendees in Washington, D.C., to showcase innovative strategies aimed at improving clinical, financial, and operational performance.

    Kicking off the summit, Keith Dunleavy, M.D., CEO and Founder of Inovalon, brought attendees through a technological innovation journey to highlight AI, machine learning, and data's impact on healthcare. Dunleavy shared, "We have an opportunity to make healthcare better, but we need to fully embrace the rapid progression of software sophistication and technology. We need to be willing to take on innovation at a faster, more uncomfortable pace."

    Applying AI in Healthcare, Today and Tomorrow



    AI innovation took center stage at Empower, with many sessions illustrating its transformative potential across the healthcare ecosystem. Industry leaders Rajesh Viswanathan, CTO at Inovalon, Rahul Pathak, VP of Gen AI and AI/ML GTM at AWS (NASDAQ:AMZN), Vinod Mamtani, VP, AI and Data Science Services at Oracle Cloud Infrastructure (NYSE:ORCL), and Murali Gandhirajan, Global Healthcare CTO at Snowflake (NYSE:SNOW), shared their perspectives on where the biggest opportunities in technology exist and their vision for how AI will unfold in the future of healthcare. The panel agreed that AI is a powerful force multiplier poised to personalize care interactions, automate workflows, and accelerate drug development. But they were clear: organizations must lean into these advancements or risk being left behind, and as the industry embraces emerging technology to assist, augment, and accelerate outcomes, those who commit will lead the way in delivering more efficient, impactful care.

    Modernizing the Healthcare System

    Former CDC Director, Rochelle Walensky, M.D., MPH, joined Inovalon's Chief Medical Officer, Dr. Paige Killian, M.D., on stage at Empower to advocate for data modernization across the healthcare and public health systems. Dr. Walensky provided first-hand perspective on the data challenges that the U.S. public health infrastructure faced during the pandemic and other outbreaks while she worked in the CDC and the difficulties with collecting and integrating a vast amount of data from various sources and formats in a timely manner. She emphasized that to get actionable data before we get past the peak of an outbreak or even the next pandemic, we must educate and upskill the healthcare workforce in data analysis and AI. This emphasis on the role of the healthcare and public health workforce in data modernization was a recurring theme throughout the conference, with all participants and speakers agreeing that a modern data strategy serves as the foundation for any successful public health, AI, or technology strategy.

    Maximizing Real-World Evidence and Utilizing SDOH Data to Improve Outcomes



    An additional theme at Empower was the benefit of unlocking real-world evidence (RWE) and social drivers of health (SDOH) data to create a more equitable healthcare ecosystem. While clinical trials are essential for determining drug safety and efficacy, they are prone to gaps in understanding the patient's experience and real-world outcomes. Industry experts, including Christie Teigland, Ph.D., VP of Research Science & Advanced Analytics at Inovalon, Todd Sharp, Head of Strategy & Transformation for Healthcare and Life Sciences at AWS (NASDAQ:AMZN), and Brett Kay, Director of Healthcare Quality Strategy at Johnson & Johnson (NYSE:JNJ), shared strategies for activating RWE and SDOH data to support vulnerable and underrepresented populations. With SDOH contributing to up to 80% of health outcomes, these sessions highlighted opportunities for leveraging data to bridge care gaps and improve cross-industry collaboration. But first, it was clear there must be a push to reduce disparate data sources, improve health literacy, and actively fight against health disparities to improve representation and care across the healthcare continuum.

    The Future of Patient-Centric Cell and Gene Therapies



    Cell and gene therapies have transformed how the healthcare industry treats and potentially cures common and rare diseases. Kim Tedesco, RPh, Director of Gene & Cell Therapy Pharmacy Operations at Walgreens (NASDAQ:WBA), welcomed to the Empower stage the first patient to ever receive a CRISPR cell-based gene therapy treatment for sickle cell. The patient advocate brought attendees through her care and treatment journey while living with the crippling disease through childhood and adulthood. The session highlighted the miracles of these therapies and the essential relationships between pharmacies, providers, and health plans needed to ensure patients receive life-saving treatments.

    Advancing Data-Driven Healthcare: Seven New Software Solutions and Feature-Set Expansions Announced

    In a continued effort to drive ever-greater impact across the healthcare continuum, Inovalon unveiled seven new products and features to help providers, payers, pharmacies, and life sciences prioritize data-driven healthcare.

    The Eligibility Verification Pro solution improves revenue cycle management by simplifying providers' ability to accurately verify patients' insurance coverage, reducing claims denials, and improving cash flow. For health plans, Inovalon announced Converged Provider Enablement to turn cost and utilization data into actionable insights, Converged Record Review to automate manual medical record reviews and improve risk score accuracy, and Converged Outreach Connectors to provide secure, seamless member data sharing capabilities. Additionally, the company also launched a Research Network to help health systems and life sciences organizations accelerate access to clinical trials and life-saving therapies. Finally, Inovalon is expanding the feature set of ScriptMed and debuted the new Inovalon Application Portal to provide customers with a centralized hub to find and launch all Inovalon ONE® Platform applications.

    Additional details on the product news can be found on Inovalon's website here: https://www.inovalon.com/news/inovalon-launches-seven-new-software-solutions-and-feature-set-expansions-to-drive-ever-greater-impact-across-the-healthcare-continuum/.

    "Empower 2024 showed us that the technology revolution poised to transform healthcare isn't lifetimes away – it's right around the corner," said Eron Kelly, President of Inovalon. "Inovalon is leading the charge in data-driven healthcare transformation. Together, with our customers and partners, we are shifting from a reactive, episodic industry to a more predictive and preventive system where data, AI, and personalization are shaping the future of healthcare."

    Experience Empower 2024's best moments here: https://www.inovalon.com/empower/.





    About Inovalon

    Inovalon is a leading provider of cloud-based SaaS solutions empowering data-driven healthcare. The Inovalon ONE® Platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics into a sophisticated cloud-based platform empowering improved outcomes and economics across the healthcare ecosystem. The company's analytics and capabilities are used by nearly 20,000 customers supporting more than 53,000 sites of care, and are informed by the primary source data of more than 85 billion medical events across 1.1 million physicians, 677,000 clinical settings, and 395 million unique lives. For more information, visit www.inovalon.com.

    Contact:

    Tom Paolella

    Sr. Director, Press and Analyst Relations, Inovalon

    [email protected]



    Primary Logo

    Get the next $AMZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMZN
    $JNJ
    $ORCL
    $SNOW

    CompanyDatePrice TargetRatingAnalyst
    Amazon.com Inc.
    $AMZN
    11/4/2025$300.00 → $315.00Outperform
    Mizuho
    Amazon.com Inc.
    $AMZN
    10/31/2025$275.00 → $300.00Overweight
    Barclays
    Amazon.com Inc.
    $AMZN
    10/31/2025$285.00 → $300.00Mkt Outperform
    Citizens JMP
    Amazon.com Inc.
    $AMZN
    10/31/2025$280.00 → $300.00Buy
    Canaccord Genuity
    Amazon.com Inc.
    $AMZN
    10/31/2025$280.00 → $292.00Overweight
    Wells Fargo
    Amazon.com Inc.
    $AMZN
    10/31/2025$270.00 → $320.00Buy
    Citigroup
    Amazon.com Inc.
    $AMZN
    10/31/2025$272.00 → $303.00Buy
    BofA Securities
    Amazon.com Inc.
    $AMZN
    10/31/2025$265.00 → $305.00Overweight
    Analyst
    More analyst ratings

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rubinstein Jonathan sold $2,043,495 worth of shares (8,173 units at $250.03), decreasing direct ownership by 9% to 80,030 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    11/4/25 8:41:38 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    CEO Worldwide Amazon Stores Herrington Douglas J sold $6,139,260 worth of shares (24,500 units at $250.58), decreasing direct ownership by 5% to 491,007 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    11/4/25 8:32:57 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    EVP, Product Management Kleinerman Christian sold $4,152,300 worth of shares (15,000 units at $276.82), decreasing direct ownership by 2% to 522,450 units (SEC Form 4)

    4 - Snowflake Inc. (0001640147) (Issuer)

    11/4/25 5:02:35 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho reiterated coverage on Amazon with a new price target

    Mizuho reiterated coverage of Amazon with a rating of Outperform and set a new price target of $315.00 from $300.00 previously

    11/4/25 10:48:43 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Barclays reiterated coverage on Amazon with a new price target

    Barclays reiterated coverage of Amazon with a rating of Overweight and set a new price target of $300.00 from $275.00 previously

    10/31/25 11:26:50 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Citizens JMP reiterated coverage on Amazon with a new price target

    Citizens JMP reiterated coverage of Amazon with a rating of Mkt Outperform and set a new price target of $300.00 from $285.00 previously

    10/31/25 11:26:39 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    SEC Filings

    View All

    SEC Form 13F-HR filed by Amazon.com Inc.

    13F-HR - AMAZON COM INC (0001018724) (Filer)

    11/4/25 4:13:47 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 144 filed by Snowflake Inc.

    144 - Snowflake Inc. (0001640147) (Subject)

    11/3/25 12:19:03 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Amazon.com Inc.

    10-Q - AMAZON COM INC (0001018724) (Filer)

    10/30/25 6:18:21 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oracle and Ci4CC Partner to Accelerate Oncology Innovation

    Strategic collaboration to leverage Ci4CC's national network and Oracle's technology to help advance AI in oncology, EHR interoperability, next-gen clinical trials, and personalized medicine MIAMI BEACH, Fla., Nov. 7, 2025 /PRNewswire/ -- 24th Cancer Center Informatics Society Symposium -- Oracle Health and Life Sciences and the Cancer Center Informatics Society (Ci4CC), a nonprofit uniting cancer centers, researchers, and industry innovators, are collaborating to advance AI innovation in oncology care and research. The collaboration aims to bring together Oracle's technology

    11/7/25 9:45:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

    Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring   Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time  HORSHAM, Pa., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease

    11/6/25 5:07:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

    CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2  In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of patients reaching remission from depression3 CAPLYTA® offers a new option for the 2 in 3 people who experience residual symptoms despite their current antidepressant treatment1,2,3 TITUSVILLE, N.J., Nov. 6, 2025 /PRNewswire/ -- Joh

    11/6/25 7:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Leadership Updates

    Live Leadership Updates

    View All

    Snowflake Intelligence Brings Agentic AI to the Enterprise

    From Fortune 500 companies like Cisco, to global enterprises like Toyota Motor Europe, and sports teams like USA Bobsled/Skeleton Team, organizations in every industry are leveraging Snowflake Intelligence to democratize data and AI throughout their business Innovations such as Cortex Agents, Cortex Knowledge Extensions, and Snowflake managed MCP Server provide the building blocks that users need to create powerful, custom AI solutions More than 1,000 Snowflake customers have already leveraged Snowflake Intelligence to deploy over 12,000 AI agents across their businesses, and that number continues to grow Snowflake (NYSE:SNOW), the AI Data Cloud company, today announced that Snowflak

    11/4/25 9:10:00 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    USA Bobsled/Skeleton Taps Snowflake Intelligence to Redefine Speed and Precision on Ice

    Winter is coming! USABS will leverage Snowflake's world-class data and AI platform to gain crucial insights to support athletes, optimize sled technology and enhance strategic decision-making on ice USA Bobsled/Skeleton (USABS) selects Snowflake as the Official Data Cloud Provider aligning shared values of speed and excellence in the run up to the Olympic and Paralympic Winter Games Milano Cortina 2026 Snowflake's technology will provide coaches with fast, actionable data to make micro-adjustments to athlete technique Partnership extends on Snowflake's commitment to bringing best-in-class innovation to Team USA and the LA28 Olympic and Paralympic Games as their Official Data Collab

    11/3/25 9:05:00 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Financials

    Live finance-specific insights

    View All

    Snowflake to Announce Financial Results for the Third Quarter of Fiscal 2026 on December 3, 2025

    Snowflake (NYSE:SNOW), the AI Data Cloud company, today announced it will release its financial results for the third quarter of fiscal year 2026, which ended October 31, 2025, following the close of the U.S. markets on Wednesday, December 3, 2025. Snowflake will host a conference call to discuss the financial results. Conference Call Details The conference call will begin at 3 p.m. Mountain Time on December 3, 2025. Investors and participants may attend the call by dialing (833) 470-1428 (Access code: 752353). For investors and participants outside the United States, see global dial-in numbers here (Access code: 752353). The call will also be webcast live on the Snowflake Investor Re

    11/3/25 9:00:00 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Amazon.com Announces Third Quarter Results

    Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its third quarter ended September 30, 2025. Net sales increased 13% to $180.2 billion in the third quarter, compared with $158.9 billion in third quarter 2024. Excluding the $1.5 billion favorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 12% compared with third quarter 2024. North America segment sales increased 11% year-over-year to $106.3 billion. International segment sales increased 14% year-over-year to $40.9 billion, or increased 10% excluding changes in foreign exchange rates. AWS segment sales increased 20% year-over-year to $33.0 billion.

    10/30/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon.com to Webcast Third Quarter 2025 Financial Results Conference Call

    Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20251016136519/en/ Amazon.com Public Relations [email protected] amazon.com/ir

    10/16/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Snowflake Inc.

    SC 13G/A - Snowflake Inc. (0001640147) (Subject)

    11/12/24 5:50:12 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    11/8/24 4:33:15 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

    11/7/24 5:23:12 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary